September 12, 2022
|
The Division of Mental Health and Addiction Services (DMHAS) has announced changes to the Substance Use Disorder (SUD) Fee for Service (FFS) Initiatives Contract Enhancement Package (Vivitrol) to include Buprenorphine and associated services. The addition of Buprenorphine/Suboxone medications and services to the Vivitrol packages will be offered effective November 1, 2022 to licensed SUD provider agencies that have a Certificate of Waiver for Medication Assisted Treatment issued to their sites by the Department of Health Certificate of Need and Licensing (CN&L), pursuant to N.J.A.C. 8:43. Currently, licensed Opioid Treatment Providers (OTP) sites in the SUD FFS Network can access Buprenorphine/Suboxone through the Medication Assisted - Buprenorphine Enhancement package; therefore, this contract revision does not apply to OTPs. A Certificate of Waiver for Medication Assisted Treatment is required for licensed sites to provide Vivitrol and Buprenorphine/Suboxone. Any site that does not have the waiver will no longer be able to be reimbursed for Vivitrol and will not be able to be reimbursed for Buprenorphine/Suboxone through FFS. SUD FFS contract modifications will be forwarded to agencies, notifying them of any contract changes. Providers licensed to provide Methadone will remain eligible for reimbursement for Buprenorphine/Suboxone, as well as Methadone. This expansion to include Buprenorphine and associated services is a major advocacy win for NJAMHAA, which has been working to get this implemented for years; SUD treatment providers; and those struggling with addiction. Click here to access the notice from DMHAS and for more information. |
